IL7R and leukemia: This switch in growth factor dependency was confirmed in vivo, where the acquired IL-7-independence of leukemia cells was sufficient to sustain the expansion of leukemic blasts in NSG recipients treated with IL-7R-blocking antibody (Fig. 4D).